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 ABSTRACT 
 Acute puerperal metritis (APM) is one of the most 
common diseases during the puerperal period. Systemic 
administration of ceftiofur for 5 consecutive days has 
been shown to be effective for treatment of APM. The 
objective of this study was to determine concentrations 
of ceftiofur derivatives in serum, endometrial tissue, 
and lochia of cows with fever postpartum or APM 4 to 
6 d after treatment with a single subcutaneous dose of 
6.6 mg of ceftiofur crystalline free acid (CCFA)/kg of 
estimated BW at the base of the ear. In the first ex-
periment, samples from CCFA-treated cows with fever 
postpartum or APM (n = 42) were taken on d 4, 5, or 6 
after treatment. Concentrations of ceftiofur derivatives 
were quantified using an HPLC assay. Concentrations 
of active ceftiofur metabolite desfuroylceftiofuracet-
amide (DCA) were greatest at d 4 after treatment with 
CCFA in all samples, but they were considerably lower 
than the concentrations of DCA in healthy postpar-
tum cows treated with the same dose of CCFA. The 
concentrations of DCA in serum, endometrial tissue, 
and lochia were affected by odor of vaginal discharge 
before treatment with CCFA. Mean concentrations of 
DCA could be detected above the reported minimal 
drug concentrations (minimum inhibitory concentra-
tions, MIC) required to inhibit relevant pathogens such 
as Escherichia coli and Arcanobacterium pyogenes in 
serum on all days and in endometrial tissue and lochia 
only on d 4 in CCFA-treated cows with fetid vaginal 
discharge before treatment. In the second experiment, 
samples from CCFA-treated cows with APM (n = 8) 
were taken on d 0 (before treatment) and d 4, 5, and 6 
after treatment. Mean concentrations of DCA in serum 
and lochia were similar on d 4 to 6 in both laboratories. 
Furthermore, determined concentrations of DCA from 
both laboratories were correlated for serum and lochia. 
Mean concentrations of DCA could be detected above 
the reported MIC in serum and lochia only on d 4. Our 
2 experiments demonstrated that in postpartum cows 
with fever postpartum or APM concentrations above 
the MIC for relevant bacteria (>0.5 μg/mL or >0.5 
μg/g) of DCA could be sustained only for 4 (serum: 
15/17; endometrial tissue: 2/17; lochia: 1/16) to 5 d 
(serum: 10/13; endometrial tissue: 1/13; lochia: 2/12) 
after a single treatment with CCFA only in a certain 
proportion of cows. Overall, our data provide first 
pharmacological evidence that a single subcutaneous 
administration of 6.6 g of CCFA/kg of BW might not 
be sufficient to efficaciously treat APM in postpartum 
dairy cows. 
 Key words:   acute puerperal metritis ,  ceftiofur ,  mini-
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 INTRODUCTION 
 Puerperal uterine infections are associated with de-
creased reproductive performance in dairy cows (Gilbert 
et al., 2005). Acute puerperal metritis (APM) is one of 
the most common diseases during the puerperal period 
(Galvão et al., 2009). Within 21 d postpartum APM 
is characterized by an abnormally enlarged uterus and 
a fetid watery red-brown uterine discharge, associated 
with signs of systemic illness (decreased milk yield, 
dullness, or other signs of toxemia) and fever >39.5°C 
(Sheldon et al., 2006). Pyrexia is associated with the 
presence of specific uterine pathogens such as Esch-
erichia coli and Arcanobacterium pyogenes, combined 
with certain anaerobic species such as Fusobacterium 
necrophorum and Prevotella melaninogenicus (Sheldon 
and Dobson, 2004). But fever is only an indicator for 
postpartum inflammation. Additional clinical signs 
such as uterine discharge are necessary to identify uter-
ine bacterial infection (Sheldon et al., 2004b). A fetid 
mucus odor is associated with the bacterial growth 
densities for Trueperella pyogenes and E. coli (Williams 
et al., 2005). In previous studies, the definitions for 
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puerperal metritis in early postpartum cows varied 
from mere fever (Zhou et al., 2001; Drillich et al., 2003; 
Drillich et al., 2007a) to fetid uterine discharge (Ma-
teus et al., 2002; Melendez et al., 2004; Jeremejeva et 
al., 2010) or a combination of both signs (Drillich et 
al., 2001; Risco and Hernandez, 2003; Chenault et al., 
2004; Drillich et al., 2007b; Galvão et al., 2009; Dubuc 
et al., 2011).
Ceftiofur (CEF) is a third-generation cephalosporin 
and highly effective against almost all gram-positive 
and gram-negative pathogens (Salmon et al., 1996). It 
is hydrolyzed to the active metabolite desfuroylceftio-
furacetamide (DCA) in the liver. After a single CEF 
treatment in healthy postpartum cows (Okker et al., 
2002) or CEF treatment (1 mg/kg of BW s.c.) for 3 con-
secutive days (Drillich et al., 2006a) in puerperal cows 
with retained fetal membranes (Drillich et al., 2006b), 
DCA could be detected in concentrations above the re-
ported MIC required to inhibit relevant pathogens such 
as E. coli (0.5 μg /mL) and T. pyogenes (0.125 μg/mL). 
Systemic administration of CEF has been shown to be 
effective for treatment of APM (Drillich et al., 2001; 
Chenault et al., 2004). Ceftiofur also reduced the inci-
dence of APM in cows with retained fetal membranes 
(Drillich et al., 2003; Drillich et al., 2006b). In the Unit-
ed States and Europe, CEF has been approved for the 
treatment of APM for 5 consecutive days. A survey on 
antibiotic usage conducted on 113 dairy farms identi-
fied failure to complete antimicrobial treatment course 
in 76% of the responding herds (Sawant et al., 2005). 
Anecdotal evidence from the practice suggests that, on 
average, only 2 to 3 treatments are administered for 
therapy of APM with the potential risk of suboptimal 
cure rates and reduced reproductive performance.
Ceftiofur crystalline free acid (CCFA; Naxcel; Pfizer 
Animal Health GmbH, Berlin, Germany), a sustained-
release formulation of CEF, has been approved for a 
single subcutaneous injection at the base of the ear with 
the indication of acute bovine interdigital necrobacil-
losis in the United States and Europe. Additionally, 
in Europe a single subcutaneous treatment of CCFA 
can be used for APM in cases where treatment with 
another antimicrobial has failed. As stated in the Euro-
pean label claim of CCFA, total plasma concentrations 
above 1.0 μg of DCA/mL should be maintained for at 
least 4 d after application. After a single administration 
of CCFA in healthy postpartum cows DCA concentra-
tions exceeded the MIC for E. coli and T. pyogenes in 
serum, lochia, and endometrial tissue over a 7-d period 
(Witte et al., 2011). But no information is available 
about concentrations of DCA after a single subcuta-
neous treatment with CCFA in cows with APM. In 
the United States, CCFA is indicated for treatment of 
APM (0 to 10 d postpartum) associated with bacterial 
organisms susceptible of CEF in lactating dairy cattle 
in a 2-dose regimen 72 h apart. Therefore, the objective 
of this study was to determine concentrations of CEF 
derivatives in serum, endometrial tissue, and lochia of 
cows with APM 4 to 6 d after treatment with a single 
subcutaneous dose of 6.6 mg of CCFA/kg of estimated 
BW at the base of the ear.
MATERIALS AND METHODS
All procedures in this trial were conducted according 
to the International Cooperation on Harmonization of 
Technical Requirements for Registration of Veterinary 
Medicinal Products (VICH, Brussels, Belgium) regu-
lations relating to Good Clinical Practice and Clini-
cal Trials (GCP). The participating farmers and the 
local veterinarians were informed about all relevant 
characteristics of the study design (informed consent). 
The objective of a first experiment was to determine 
concentrations of DCA in serum, lochia, and endome-
trial tissue of lactating cows with APM after a single 
subcutaneous administration of CCFA 4 to 6 d after 
treatment. Because the results of this trial were unex-
pected a second experiment was conducted to corrobo-
rate findings by comparing the concentrations of DCA 
in serum and lochia of cows with APM after single 
subcutaneous treatment with CCFA in 2 independent 
laboratories.
Experiment 1
Study Animals. Experiment 1 was conducted on 
2 commercial dairy farms in Brandenburg, Germany, 
owned by the same farmer. Herd sizes were 1,025 (herd 
A) and 1,162 (herd B) cows. Animals were housed 
in freestall facilities with cubicles, rubber mats, and 
slotted floors all year round. Cows were dried off 45 d 
before the expected date of calving. Four weeks before 
expected calving, cows were housed in a freestall barn 
with straw bedding and fed a TMR consisting of 49.1% 
grass silage, 43.9% corn silage, 6.5% barley straw, and 
0.5 mineral mix (NEL = 1.43 Mcal/kg), distributed 2 
times per day. Lactating cows were fed a TMR con-
sisting of 2.5% mineral mix, 35.2% grass silage, 32.2% 
corn silage, 20.1% pressed pulps, 3.8% rape seed, 3.8% 
soybean meal, and 2.5% sugar beet pulp (NEL = 1.55 
Mcal/kg), distributed 2 times per day after milking. 
Average milk yields were 9,200 kg per lactation (4.2% 
fat and 3.3% protein) and 9,300 kg per lactation (4.2% 
fat and 3.3% protein) in herd A and B, respectively. 
Cows calving between May 2010 and December 2010 
were included (n = 42).
Study Design. Relevant data were recorded for each 
cow, including the calving process (1 = no assistance, 
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2 = slight assistance, and 3 = needed assistance), 
retention of fetal membranes, and number of calves. 
Concomitant treatments [e.g., fluid therapy and non-
steroidal antiinflammatory drugs (NSAID)] were given 
at the discretion of the attending veterinarian and re-
corded. For 6 d after enrollment, additional or escape 
antimicrobial treatment was only allowed if the cow’s 
life was in danger. Cows with a caesarean section and 
cows that were not supposed to be bred after calving 
were not enrolled in the study.
Rectal temperature of all postpartum cows was mea-
sured daily between 0500 and 0800 h for 10 d after calv-
ing. Cows experiencing a rectal temperature of ≥39.5°C 
(Zhou et al., 2001) once during this period received 
treatment consisting of a single subcutaneous dose of 
6.6 mg of CCFA/kg of estimated BW at the base of the 
ear. Additionally odor (fetid or nonfetid) and texture 
(watery or viscous) of vaginal discharge was recorded 
at the day of enrollment according to the definition of 
APM by Sheldon et al. (2006). After enrollment, rectal 
temperature was measured for 6 more days.
To determine the concentrations of DCA in serum, 
endometrial tissue and lochia of CCFA-treated cows 
with fever postpartum (n = 29) or APM (n = 13), 
samples of blood, endometrial tissue, and lochia were 
collected on d 4 (n = 12), 5 (n = 17), or 6 (n = 13) after 
enrolment. A cow was considered clinically cured if an 
antimicrobial escape therapy had not been administered 
during 6 d after enrolment and rectal temperature was 
<39.5°C at the end of the observation period.
Experiment 2
Study Animals. Experiment 2 was conducted on 
a commercial dairy farm in Brandenburg, Germany, 
with a herd size of 643 cows. Cows were dried off 45 
d before the expected date of calving and housed in a 
tiestall barn with straw bedding. Cows from calving 
to 7 DIM belonged in this group. These cows received 
64.7% grass silage, 32.8% corn silage, 1.7% hay, 0.3% 
corn, and 0.5% mineral mix (NEL = 1.49 Mcal/kg) dis-
tributed 3 times per day. The average milk yield was 
8,382 kg per lactation (4.27% fat and 3.61% protein). 
Seventeen cows calving in July 2011 were included in 
this trail.
Study Design. The rectal temperature of postpar-
tum cows was measured daily between 1000 and 1100 
h for 5 d after calving. Cows experiencing a rectal tem-
perature of ≥39.5°C (Zhou et al., 2001) once during this 
period were assigned to the treatment group (n = 8) 
and received treatment consisting of a single subcuta-
neous dose of 6.6 mg of CCFA/kg of estimated BW at 
the base of the ear. Healthy cows experiencing a rectal 
temperature of <39.5°C during this period remained 
untreated and served as controls (n = 9). After en-
rollment, rectal temperature was measured for 7 more 
days. In the control group, blood and lochia samples 
for baseline concentrations were collected at 5 DIM. In 
the CCFA group, blood and lochia samples were taken 
for baseline before treatment on d 0 and additional 
samples after treatment on d 4, 5, and 6.
Methods of Sampling
Blood samples were collected by coccygeal venipunc-
ture using sterile vacuum tubes (Venoject II; Terumo 
Europe NV, Leuven, Belgium). Blood samples were 
centrifuged at 3,500 × g for 8 min at room temperature. 
Serum was divided into 2 aliquots, transferred into se-
rum tubes, and stored at −20°C until analysis.
Before collection of samples from the uterus, the 
vulva and perineum were cleaned with dry paper tow-
els. Biopsy samples of experiment 1 were taken from 
the base of either horn with a Kevorkian biopsy forceps 
[Wirtschaftsgenossenschaft deutscher Tierärzte eG 
(WDT), Garbsen, Germany) as described by Witte et 
al. (2011). A sample of uterine tissue (approximately 
0.15 g) was collected under transrectal control. The col-
lected tissue was stored in sterile plastic tube (Eppen-
dorf AG, Hamburg, Germany) at −20°C until further 
analysis.
Finally, 1 sterile-gloved hand was introduced through 
the vagina into the uterus lumen and at least 10 mL of 
lochia was collected into Rotilabo screw-cap cans (Carl 
Roth GmbH & Co. KG, Karlsruhe, Germany). Two 
aliquots of 5 mL each were stored in sterile milk tubes 
(Sarstedt AG & Co., Nürnberg, Germany) at −20°C 
for further analysis. Additionally, from 1 healthy, 
nontreated cow, 100 mL of serum, 10 g of endometrial 
tissue, and 100 mL of lochia were collected within 4 d 
after calving as blank material for HPLC analysis.
Analytical Methods
In experiment 1, concentrations of CCFA (molecular 
weight = 523.56 g/mol) residues were quantified in 
serum, endometrial tissue, and lochia samples using an 
HPLC assay with small modifications as described by 
Drillich et al. (2006a) and Witte et al. (2010, 2011). 
In this method, residues of CCFA were converted into 
DCA (molecular weight = 486.54 g/mol), which was 
determined by liquid chromatography-mass spectrome-
try (LC-MS). The limit of quantification of the method 
was 0.1 μg of DCA/mL for serum and 0.1 μg of DCA/g 
in lochia and endometrial tissue.
In experiment 2, all samples were sent to 2 independent 
laboratories for analysis of concentrations of CCFA in 
serum and lochia. The first laboratory was the same as 
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in experiment 1, conducting the same methods. In the 
second laboratory, residues of CCFA including metabo-
lites were converted into DCA, which was determined 
by HPLC. In brief, 0.2 mL of serum or 0.5 g of lochia 
was mixed with 0.8 mL of water and 4.0 mL of sodium 
phosphate (0.01 M) and sodium hydroxide solution (0.1 
N) at pH 8.2 to 8.7, adding 100 mg of dithioerythritol, 
and incubated at 50°C for 15 min. After elution of DCA 
from a Bond Elut C18-solid-phase extraction (SPE) 
cartridge (Agilent Technologies, Lake Forest, CA), the 
eluates were passed over a cation-exchange SCX SPE 
column (Agilent Technologies). The extract was then 
determined by HPLC. The limit of quantification of the 
method was 0.05 μg of CCFA/mL for serum and 0.02 
μg of CCFA/g in lochia.
Statistical Analyses
Concentrations of DCA of ≥0.5 μg/mL or ≥0.5 μg/g 
and ≥0.125 μg/mL or ≥0.125 μg/g are relevant for the 
potential efficacy of a treatment against E. coli and 
T. pyogenes (Sheldon et al., 2004a). Therefore, these 
concentrations were regarded as threshold values, as 
described by Drillich et al. (2006a). All data were re-
corded on data capture forms and transferred into a 
spreadsheet (Excel 2010; Microsoft, Munich, Germany). 
Descriptive statistical analyses were carried out with 
PASW (version 18.0; SPSS Inc. Munich, Germany). 
Results are presented as means ± standard error of 
the mean. Correlations between concentrations of DCA 
in serum, endometrial tissue, and lochia were tested 
using the Spearman rank correlation (rs) for nonpara-
metric variables. A linear regression model was run to 
calculate if DCA concentrations in serum would be a 
predictor for DCA concentrations in endometrial tissue 
and lochia, including odor of vaginal discharge on the 
day of treatment and time after treatment as covari-
ates. Univariate ANOVA was performed to determine 
effects of plausible factors [i.e., day of sampling (4 to 6), 
odor of lochia (fresh vs. fetid), and interactions between 
these factors].
Correlations between the 2 laboratories for concen-
trations of DCA in serum and lochia were tested using 
the Pearson correlation (r) for parametric variables. A 
clinical measurement comparison can be inappropriate 
using Pearson correlation. Therefore, the agreement 
between the different laboratories was graphically ana-
lyzed using the method of Bland and Altman (1986) 
with MedCalc (version 12.0.3.0.; MedCalc software 
bvba, Mariakerke, Belgium).
Correlation coefficients, adjusted correlation coeffi-
cients, confidence intervals, and P-values are reported. 
For Univariate ANOVA, confidence intervals were set 
at 95%. For all statistical analyses, the level of signifi-
cance was set at α = 0.05.
RESULTS
Experiment 1
The greatest DCA concentrations in serum, endome-
trial tissue, and lochia, respectively, were detected at 
d 4 after administration of CCFA (Table 1). Serum 
concentrations of DCA exceeded the reported MIC of 
0.5 μg/mL for E. coli in most of the CCFA-treated 
cows. In few serum samples, concentrations of DCA 
were below 0.5 μg/mL at d 4 (n = 1/12), 5 (n = 2/17), 
and 6 (n = 3/13) after administration of CCFA (Table 
2). The concentrations of DCA in serum, however, were 
above the MIC for T. pyogenes, F. necrophorum, and 
Prevotella melaninogenica (0.125 μg/mL) for all CCFA-
treated cows.
In endometrial tissue, mean concentrations of DCA 
were above the MIC for E. coli (0.5 μg/mL) and MIC 
for T. pyogenes, F. necrophorum, and P. melaninogenica 
(0.125 μg/mL) only on d 4 in CCFA-treated cows with 
fetid vaginal discharge before treatment (n = 2/2; 
Table 2). In most of the endometrial samples of CCFA-
Table 1. Concentration of desfuroylceftiofuracetamide (DCA; mean ± SEM) in serum, endometrial tissue, and lochia on d 4, 5, and 6 after 
administration of a single dose of ceftiofur crystalline free acid (CCFA; 6.6 mg/kg of BW) 
Days after  
CCFA treatment
Odor of vaginal  
discharge at CCFA
Serum (μg/mL) Endometrial tissue (μg/g) Lochia (μg/g)
n Mean ± SEM n Mean ± SEM n Mean ± SEM
4 Fetid 1 3.521 1 0.991 1 3.521
1 0.721 1 1.311 1 0.741
Fresh 10 0.80 ± 0.15 9 0.27 ± 0.09 10 0.01 ± 0.01
Total 12 0.81 ± 0.13 11 0.43 ± 0.13 12 0.37 ± 0.29
5 Fetid 5 0.68 ± 0.13 5 0.25 ± 0.07 5 0.40 ± 0.31
Fresh 12 0.70 ± 0.09 12 0.35 ± 0.07 11 0.10 ± 0.03
Total 17 0.70 ± 0.07 17 0.32 ± 0.05 16 0.19 ± 0.10
6 Fetid 6 0.69 ± 0.11 6 0.37 ± 0.10 6 0.83 ± 0.47
Fresh 7 0.56 ± 0.05 7 0.24 ± 0.05 6 0.04 ± 0.02
Total 13 0.62 ± 0.06 13 0.30 ± 0.06 12 0.43 ± 0.26
1Data are presented for each cow individually; therefore, mean ± SEM could not be calculated.
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treated cows, concentrations of DCA were below 0.5 
μg/mL (d 4: n = 7/11, d 5: n = 15/17, d 6: n = 12/13; 
Table 2). The concentrations of DCA in endometrial 
tissue, however, were above the MIC for T. pyogenes, 
F. necrophorum, and P. melaninogenica (0.125 μg/mL) 
for CCFA-treated cows. In a few endometrial samples, 
concentrations of DCA were below 0.125 μg/mL at d 
4 (n = 3/11), d 5 (3/17), and d 6 (n = 3/13) after 
administration of CCFA (Table 2).
In lochia, mean concentrations of DCA were above 
the MIC for E. coli (0.5 μg/mL) and MIC for T. pyo-
genes, F. necrophorum, and P. melaninogenica (0.125 
μg/mL) only on d 4 in CCFA-treated cows with fetid 
vaginal discharge at the time of treatment (d 4: n = 
2/2, d 5: n = 4/5, d 6: n = 4/6; Table 2). In most of the 
lochia samples of CCFA-treated cows, concentrations 
of DCA were in the categories <0.5 μg/mL and <0.125 
μg/mL (Table 2).
The concentrations of DCA in serum, endometrial 
tissue, and lochia were affected by odor of vaginal 
discharge before treatment with CCFA. In serum, the 
day after treatment (P = 0.001) and the interaction 
between odor of vaginal discharge and day after treat-
ment (P = 0.006) had an effect on the concentrations 
of DCA (R2 = 0.36; adjusted R2 = 0.27). In lochia, the 
day after treatment (P = 0.024), odor of vaginal dis-
charge (P < 0.001), and the interaction between odor of 
vaginal discharge and day after treatment (P = 0.012) 
had an effect on the concentrations of DCA (R2 = 0.44; 
adjusted R2 = 0.36). In endometrial tissue the odor 
of vaginal discharge (P = 0.007) and the interaction 
between odor of vaginal discharge before treatment and 
day after treatment (P = 0.033) also had an effect on 
the concentrations of DCA (R2 = 0.29; adjusted R2 = 
0.18).
Correlations between concentrations of DCA in se-
rum and endometrial tissue was rs = 0.489 (P = 0.001) 
and between concentrations of DCA in endometrial tis-
sue and lochia was rs = 0.604 (P < 0.001). The correla-
tion between serum and lochia was lower (rs = 0.300; 
P = 0.060). The concentration of DCA in serum was 
a predictor for concentrations of DCA in lochia (P < 
0.001) but not for concentrations of DCA in endome-
trial tissue (P = 0.087).
Experiment 2
The greatest DCA concentrations in serum and lo-
chia were detected at d 4 after administration of CCFA 
(Table 3). Mean concentrations of DCA in serum and 
lochia were similar on d 4 to 6 in both laboratories 
(Figure 1A and B). Furthermore, determined concen-
trations of DCA from both laboratories were correlated 
for serum (r = 0.980; P < 0.01) and lochia (r = 0.944; 
P < 0.01). Serum concentrations of DCA exceeded the 
reported MIC of 0.5 μg/mL for E. coli only on d 4 after 
treatment with CCFA (Table 4). On d 5 after treat-
ment, in 2 of 8 serum samples concentrations of DCA 
were below 0.5 μg/mL, and on d 6 after treatment, in 
5 of 8 (laboratory 1) and 4 of 8 (laboratory 2) serum 
samples concentrations of DCA were below 0.5 μg/mL. 
The concentrations of DCA in serum, however, were 
above the MIC for T. pyogenes, F. necrophorum, and 
P. melaninogenica (0.125 μg/mL) for all CCFA-treated 
cows.
In lochia, DCA concentrations varied widely (Table 
3). On d 5 and 6 after treatment with CCFA, in most 
lochia samples concentrations of DCA were below 
the reported MIC of 0.5 μg/mL for E. coli for both 
laboratories. For about half of the lochia samples the 
Table 2. Number of samples (no./total no. of samples) with concentrations of desfuroylceftiofuracetamide (DCA) <0.5 and <0.125 μg/mL 
(serum) or <0.5 and <0.125 μg/g (endometrial tissue and lochia) after administration of a single dose of ceftiofur crystalline free acid (CCFA; 
6.6 mg/kg of BW) 
Days after  
CCFA treatment
Odor of vaginal  
discharge at CCFA
Concentration of DCA1
Serum2 Endometrial tissue2 Lochia2
<0.5 <0.125 <0.5 <0.125 <0.5 <0.125
4 Fetid 0/2 0/2 0/2 0/2 0/2 0/2
Fresh 1/10 0/10 7/9 3/9 10/10 10/10
Total 1/12 0/12 7/11 3/11 10/12 10/12
5 Fetid 1/5 0/5 5/5 1/5 4/5 3/5
Fresh 1/12 0/12 10/12 2/12 11/11 8/11
Total 2/17 0/17 15/17 3/17 15/16 11/16
6 Fetid 1/6 0/6 5/6 1/6 4/6 3/6
Fresh 2/7 0/7 7/7 2/7 6/6 6/6
Total 3/13 0/13 12/13 3/13 10/12 9/12
1For serum, concentrations are in μg/mL; for endometrial tissue and lochia, concentrations are in μg/g.
2Minimum inhibitory concentration required to inhibit the growth of 90% of organisms (MIC90) for Escherichia coli: <0.5 mg/mL; MIC90 for 
Arcanobacterium pyogenes, Fusobacterium necrophorum, and Prevotella melaninogenica: <0.125 mg/mL.
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concentrations of DCA were also below the MIC for 
T. pyogenes, F. necrophorum, and P. melaninogenica 
(0.125 μg/mL) for both laboratories (Table 4).
DISCUSSION
The main objective was to determine concentrations 
of CEF derivatives in serum, endometrial tissue, and 
lochia of cows with fever postpartum or APM 4 to 6 d 
after treatment with a single subcutaneous dose of 6.6 
mg of CCFA/kg of estimated BW at the base of the 
ear. At present, no other published reports are available 
about concentration of DCA in serum, endometrial tis-
sue, and lochia after single subcutaneous treatment with 
CCFA in cows with either fever postpartum or APM.
In the first experiment, concentrations of DCA were 
greatest at d 4 after treatment with CCFA in serum, 
endometrial tissue, and lochia, but they were consider-
ably lower than the concentrations of DCA in healthy 
postpartum cows (serum: 1.54 ± 0.68 μg/mL; endo-
metrial tissue: 1.19 ± 0.47 μg/g; lochia: 2.61 ± 3.89 
μg/g) treated with the same dose of CCFA (Witte et 
al., 2011). As stated in the label claim of CCFA, total 
plasma concentrations above 1.0 μg/mL of DCA should 
be maintained for at least 4 d after application. But our 
results show mean concentrations of DCA considerably 
lower: 1.0 μg/mL on d 4. On d 5, the concentrations of 
DCA in CCFA-treated APM-diseased cows were also 
below the concentrations of DCA in similar samples 
taken from healthy postpartum cows (serum: 1.21 ± 
0.61 μg/mL; endometrial tissue: 0.86 ± 0.61 μg/g; lo-
chia: 0.96 ± 1.15 μg/g) treated with the same dose of 
CCFA in a previous study (Witte et al., 2011). On d 
6, as well, the concentrations of DCA in CCFA-treated 
APM-diseased cows were considerably lower than the 
concentrations of DCA in a previous study with healthy 
postpartum cows (serum: 0.82 ± 0.42 μg/mL; endome-
trial tissue: 0.70 ± 0.68 μg/g; lochia: 2.44 ± 3.46 μg/g) 
treated with the same dose of CCFA (Witte et al., 
2011). Overall, these results contradict the hypothesis 
Table 3. Concentration of desfuroylceftiofuracetamide (DCA; mean ± SEM) in serum and lochia samples of 
ceftiofur crystalline free acid (CCFA; 6.6 mg/kg of BW)-treated cows before (d 0) and after treatment (d 4 to 
6) in 2 independent laboratories 
Matrix Day
Concentration of DCA
Laboratory 1 Laboratory 2
Serum (n = 8; μg/mL) 0 0.20 ± 0.14 0.15 ± 0.11
4 1.03 ± 0.11 1.04 ± 0.10
5 0.66 ± 0.10 0.68 ± 0.10
6 0.51 ± 0.10 0.48 ± 0.06
Lochia (n = 8; μg/g) 0 0.11 ± 0.11 0.10 ± 0.08
4 0.94 ± 0.44 1.08 ± 0.46
5 0.11 ± 0.06 0.21 ± 0.15
6 0.18 ± 0.14 0.26 ± 0.15
Figure 1. Bland-Altman plots comparing concentrations of desfu-
roylceftiofuracetamide (DCA) measured by 2 different laboratories in 
serum (A) and lochia (B) of cows treated with a single subcutaneous 
dose of 6.6 mg of ceftiofur crystalline free acid/kg of estimated BW at 
the base of the ear.
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that the concentration of DCA would be higher at the 
uterine level in cows with APM (Okker et al., 2002). 
The concentration of DCA in serum can be used to 
predict the concentration of DCA in lochia but not in 
endometrial tissue. Nevertheless, mean concentrations 
of DCA were higher in cows with fetid vaginal discharge 
before treatment in endometrial tissue and lochia at d 
4 and 6 and in lochia at d 5 than in cows with odorless 
vaginal discharge. Also, a significant effect of odor of 
vaginal discharge before CCFA treatment was found on 
mean concentrations of DCA in endometrial tissue (P 
= 0.007) and lochia (P < 0.001).
In previous studies, the definitions for puerperal me-
tritis in early postpartum cows varied from mere fever 
(Zhou et al., 2001; Drillich et al., 2003, 2007a) to fetid 
uterine discharge (Mateus et al., 2002; Melendez et al., 
2004; Jeremejeva et al., 2010) or a combination of both 
signs (Drillich et al., 2001, 2007b; Risco and Hernan-
dez, 2003; Chenault et al., 2004; Galvão et al., 2009; 
Dubuc et al., 2011). It can be assumed that in this 
study, cows with fever ≥39.5°C and fetid, watery, red-
brown vaginal discharge had a case of APM (Sheldon 
et al., 2006). Cows with other diseases such as retained 
fetal membranes, mastitis, or lameness were excluded. 
Therefore, study animals with fever were considered to 
have a puerperal infection and included in the study 
group. It can be assumed that DCA accumulated in 
the inflamed endometrial tissue and lochia. This is in 
agreement with previous findings that the concentra-
tions of DCA were higher at bacterially induced inflam-
matory sites of tissue chambers (Clarke et al., 1996). 
However, we are aware that a gold standard for APM 
does not exist (Sheldon et al., 2006) and fever plus fetid 
discharge or fever alone might be imperfect criteria for 
diagnosing cows with bacterial infections of the uterus 
that require antibiotic treatment, even though those 
criteria a used in research and in the field.
Time above the MIC is the pharmacokinetic (PK) 
parameter most associated with efficacy of antibiotics. 
Serum concentrations above the MIC are important for 
an efficacious treatment of systemic infectious diseases 
associated with fever, such as APM. Serum concentra-
tions of DCA exceeded the reported MIC of 0.5 μg/
mL for E. coli (Sheldon et al., 2004a) in most of the 
CCFA-treated cows. In single samples, however, con-
centrations of DCA decreased to <0.5 μg/mL (1, 1, 
and 3 samples on d 4, 5, and 6, respectively; Table 2). 
Serum concentrations of DCA exceeded the reported 
MIC for T. pyogenes, F. necrophorum, and P. mela-
ninogenica (0.125 μg/mL) for all CCFA-treated cows. 
These results are in agreement with a previous study 
treating healthy postpartum cows with CCFA (Witte 
et al., 2011).
In endometrial tissue, mean concentrations of DCA 
were above the MIC for E. coli and MIC for T. pyo-
genes, F. necrophorum, and P. melaninogenica only on 
d 4 in CCFA-treated cows with fetid vaginal discharge 
before treatment (Table 2). In most of the endometrial 
samples of CCFA-treated cows, concentrations of DCA 
were below 0.5 μg/g (Table 2). These results disagree 
with a previous study (Witte et al., 2011) that dem-
onstrated mean concentrations of DCA in endometrial 
Table 4. Number of samples (no./total no. of samples) with concentrations of desfuroylceftiofuracetamide 
(DCA) <0.5 and <0.125 μg/mL (serum) or <0.5 and <0.125 μg/g (lochia) before (d 0) and after administration 
(d 4 to 6) of a single dose of ceftiofur crystalline free acid (CCFA; 6.6 mg/kg of BW) in 2 independent 
laboratories (Lab 1 and Lab 2) 




<0.5 <0.125 <0.5 <0.125
0
 Lab 1 7/8 6/8 7/8 7/8
 Lab 2 6/8 6/8 7/8 6/8
4
 Lab 1 0/8 0/8 5/8 4/8
 Lab 2 0/8 0/8 5/8 3/8
5
 Lab 1 2/8 0/8 8/8 5/8
 Lab 2 2/8 0/8 7/8 6/8
6
 Lab 1 5/8 0/8 7/8 6/8
 Lab 2 4/8 0/8 6/8 5/8
1For serum, concentrations are in micrograms per milliliter; for lochia, concentrations are in micrograms per 
gram.
2Minimum inhibitory concentration required to inhibit the growth of 90% of organisms (MIC90) for Escherichia 
coli: <0.5 mg/mL; MIC90 for Arcanobacterium pyogenes, Fusobacterium necrophorum, and Prevotella melanino-
genica: <0.125 mg/mL.
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tissue of CCFA-treated healthy postpartum cows above 
the reported MIC of 0.5 μg/g for E. coli for most of 
the samples during the entire study period of 7 d. The 
concentrations of DCA in endometrial tissue, however, 
were above the MIC for T. pyogenes, F. necrophorum, 
and P. melaninogenica (0.125 μg/g) for CCFA-treated 
cows. In a few endometrial samples, concentrations of 
DCA were below 0.125 μg/mL at d 4, 5, and 6 after 
administration of CCFA (Table 2).
For lochia, results were more heterogeneous. This ob-
servation is in agreement with previous studies (Okker 
et al., 2002; Drillich et al., 2006a; Witte et al., 2011). 
The levels of DCA found in lochia were mostly ineffec-
tive against bacteria in the uterine lumen. These results 
disagree with a previous study (Witte et al., 2011) that 
demonstrated mean concentrations of DCA in lochia 
of CCFA-treated healthy postpartum cows above the 
reported MIC for most of the cows until 6 d after treat-
ment. If the study cows had fetid vaginal discharge be-
fore CCFA treatment, the mean concentrations of DCA 
in lochia on d 6 after treatment exceeded the MIC for 
E. coli and MIC for T. pyogenes, F. necrophorum, and 
P. melaninogenica (0.125 μg/g) in half of the samples. 
As it is known that true tissue concentrations, espe-
cially of water-soluble antibiotics, are underestimated 
due to dilution in extracellular fluid during the analyti-
cal process (Brown et al., 1995), in vivo and in vitro 
efficacy of antibiotics may differ.
The study design to start sampling not before d 4 
was based on previous work that demonstrated DCA 
concentrations above the MIC for 7 d (Witte et al., 
2011). Obviously, further research is necessary to study 
DCA concentrations in APM cows for the first 3 d after 
a single administration of CCFA.
Because the results of this first experiment were un-
expected and contradicted the approved product infor-
mation, a second experiment was conducted to corrobo-
rate findings by comparing the concentrations of DCA 
in serum and lochia of cows with APM after single 
subcutaneous treatment with CCFA in 2 independent 
laboratories. As the objective of this experiment was 
a comparison between laboratories, we refrained from 
collecting uterine biopsies. Concentrations of DCA were 
detected in serum and lochia of all treated cows in both 
laboratories. Mean concentrations of DCA in serum 
and lochia were similar on d 4 to 6 in both laboratories 
(Figure 1A and B). Furthermore, determined concen-
trations of DCA from both laboratories were correlated 
for serum (r = 0.980; P < 0.01) and lochia (r = 0.944; 
P < 0.01). The greatest DCA concentrations in serum 
and lochia were detected at d 4 after administration of 
CCFA (Table 3). These results agree with the results of 
experiment 1. The mean concentrations in serum and 
lochia on d 4 were higher than the mean concentrations 
of DCA in serum and lochia in experiment 1, but they 
were again lower than the results of a previous study 
with healthy postpartum cows treated with the same 
dose of CCFA (Witte et al., 2011).
Serum concentrations of DCA of both laboratories 
were above the reported MIC of 0.125 μg/mL for T. 
pyogenes, F. necrophorum, and P. melaninogenica for all 
CCFA-treated cows. This is in agreement with previous 
data from healthy postpartum cows treated with the 
same dose of CCFA (Witte et al., 2011). But serum 
concentrations of DCA exceeded the reported MIC of 
0.5 μg/mL for E. coli only at d 4 for all CCFA-treated 
cows. At d 5 and 6 after treatment with CCFA, serum 
concentrations of DCA decreased to <0.5 μg/mL in 2 
of 8 and 4 (laboratory 1) and 5 of 8 (laboratory 2) cows, 
respectively (Table 4). Serum concentrations above the 
MIC of relevant pathogens are important for success-
ful treatment of systemic infectious diseases associated 
with fever, such as APM. Our data demonstrate that 
effective serum concentrations of DCA can be sustained 
only for 4 to 5 d after a single administration of CCFA 
in postpartum cows with APM. This finding disagrees 
with previous studies about CCFA demonstrating 
sustained efficacious concentrations against bacteria 
causing acute bovine interdigital necrobacillosis over a 
7.6-d period (Hibbard et al., 2004) and effective con-
centrations above the MIC for E. coli and T. pyogenes 
in serum of healthy postpartum cows over a 7-d period 
(Witte et al., 2011).
The levels of DCA found in lochia were mostly ineffec-
tive against bacteria in the uterine lumen. Only about 
half of the lochia samples on d 4 showed concentrations 
of DCA above the MIC of 0.5 μg/g for E. coli and the 
MIC of 0.125 μg/g for T. pyogenes, F. necrophorum, 
and P. melaninogenica. On d 5 and 6, mean concentra-
tions of DCA in lochia were mostly below the MIC and 
again differed from those of healthy cows treated with 
the same dose of CCFA (Witte et al., 2011). These 
results of our second experiment confirm those from 
experiment 1.
In a recent study, a total of 1,023 lactating postpartum 
dairy cows with APM were treated twice with CCFA (n 
= 514; 6.6 mg/kg of BW; Excede Sterile Suspension; 
Pfizer Animal Health, Kalamazoo, MI) or placebo (n 
= 509) 3 d apart (McLaughlin et al., 2012). The reason 
for this approach was the finding that concentrations of 
CEF derivatives in caruncle tissue fell below the MIC of 
E. coli (0.5 μg/g) by d 3 for cows treated with a single 
dose of CCFA (data on file; Study Report No. 1535R-
60-05-495; Pfizer Animal Health ). Therefore, those 
authors postulated that 2 doses of CCFA administered 
72 h apart would effectively increase the clinical cure 
rate due to extended duration of levels of CEF above ef-
fective MIC levels for bacteria associated with metritis.
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Our 2 experiments demonstrated that in postpartum 
cows with APM, concentrations above the MIC for 
relevant bacteria (>0.5 μg/mL or >0.5 μg/g) of DCA 
can be sustained only for 4 (serum: 15/17; endome-
trial tissue: 2/17; lochia 1/16) to 5 d (serum: 10/13; 
endometrial tissue: 1/13; lochia 2/12) after a single 
treatment with CCFA only in a certain proportion of 
cows. Overall, our data provides first pharmacological 
evidence that a single subcutaneous administration of 
6.6 g of CCFA/kg of BW might not be sufficient to 
efficaciously treat APM in postpartum dairy cows.
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